Epigenomics H1 FY26 net loss narrows to EUR 128,000; revenue rises to EUR 17,000

Reuters2026/09/03 07:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Epigenomics posted a H1 2026 net loss of EUR 128,000, narrowing from EUR 204,000 a year earlier.
Revenue rose to EUR 17,000 from EUR 4,000, while other operating income increased to EUR 16,000 from EUR 7,000.
Other operating expenses fell to EUR 112,000 from EUR 188,000 due to cost-cutting, while personnel expense climbed to EUR 70,000 from EUR 50,000.
Cash and cash equivalents declined to EUR 277,000 at June 30 from EUR 414,000 at Dec. 31.
The board expects existing funds to cover costs beyond 2027, forecasting a 2026 net loss of EUR 0.2 million to EUR 0.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Epigenomics AG published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Epigenomics H1 FY26 net loss narrows to EUR 128,000; revenue rises to EUR 17,000

You may also like

Crypto prices